Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools to merge with Treeline in $2.5B deal; shareholders diluted to 16% stake
Filed June 8, 2026 · Period ending June 6, 2026 · ~1 min read
Key Changes
-
high
Standard BioTools agrees to all-stock merger with Treeline Biosciences valued at $2.5B. Existing shareholders will own only ~16% of combined company post-close, with Treeline shareholders controlling 84%—representing massive dilution.
Item 1.01: Merger Agreement verify on EDGAR → -
high
Treeline executives will lead combined company: 10 of 12 board seats go to Treeline, and Treeline's CEO, CSO, and CFO will assume all C-suite roles. Standard BioTools leadership effectively replaced.
Item 1.01: Leadership verify on EDGAR → -
high
Standard BioTools must sell or wind down its entire legacy business (mass cytometry and microfluidics). If no buyer found by registration effective date, company will begin shutdown of current operations.
Item 1.01: Legacy Business verify on EDGAR → -
medium
Shareholders receive one CVR per share for potential payments over 5 years from legacy asset sales, Illumina earnouts, and excess cash. Payments in stock, capped at 76M shares total. No guarantee of any payout.
Item 1.01: CVR Agreement verify on EDGAR → -
high
Transaction requires shareholder approval via proxy vote. Company will file S-4 registration statement. Deal expected to close second half 2026, subject to regulatory clearance and stockholder vote.
Item 8.01: Stockholder Approval view on EDGAR →
Summary
Standard BioTools has agreed to a transformative merger with Treeline Biosciences that will fundamentally reshape the company. In this all-stock deal, Treeline is valued at $2.5 billion while Standard BioTools is valued at just $460 million, resulting in existing shareholders owning only 16% of the combined entity.
Treeline will control the board (10 of 12 seats) and all executive positions, making this effectively a reverse takeover despite the legal structure. The deal requires Standard BioTools to exit its current business entirely—selling or shutting down its mass cytometry and microfluidics operations.
Shareholders will receive contingent value rights (CVRs) that may pay out over five years from asset sales and existing earnouts (including from Illumina), but these are speculative and capped. The combined company will operate under Treeline's leadership and strategy, with Standard BioTools' current operations wound down. Retail investors should watch the proxy statement (S-4 filing) for detailed financial projections and fairness opinions. The shareholder vote will be critical—this is essentially a decision to exchange your stake in Standard BioTools' existing business for a small minority position in Treeline's biotech platform. Pay close attention to whether the legacy business finds a buyer, as that will determine CVR value.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On June 6, 2026, Standard BioTools Inc., a Delaware corporation (“Standard BioTools”), entered into an Agreement and Plan of Merger and Reorganization (the “Merger Agreement”) with Treeline Biosciences, Inc., a Delaware corporation (“Treeline”), and Siri Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Standard BioTools (“Merger Sub”), pursuant to which Standard BioTools and Treeline will combine in an all-stock merger upon the terms and conditions set forth in the Merger Agreement.
Standard BioTools has agreed to merge with Treeline Biosciences in an all-stock transaction. The merger will result in Treeline becoming a wholly owned subsidiary of Standard BioTools, with the combined company changing its name to Treeline Biosciences Holdings, Inc. The transaction is structured as a tax-free reorganization and is expected to close in the second half of 2026.
Added in current filing · verify on EDGAR →
The Exchange Ratio is based on the relative capitalization of each of Treeline and Standard BioTools and assumes (i) an equity value for Treeline of $2.5 billion and (ii) an equity value for Standard BioTools equal to $460 million, reduced by the amount by which the Parent Net Cash (as defined in the Merger Agreement, which definition includes deductions for certain liabilities and costs) is less than $449 million at the closing of the Transactions (the “Closing”) or increased by the amount by which Parent Net Cash is more than $451 million at the Closing. Following the Closing, former Standard BioTools stockholders are expected to hold approximately 16% of the combined company on a fully diluted basis, and former Treeline stockholders are expected to hold approximately 84% of the combined company on a fully diluted basis.
The merger values Treeline at $2.5 billion and Standard BioTools at approximately $460 million (subject to net cash adjustments). After the transaction closes, existing Standard BioTools shareholders will own only about 16% of the combined entity, representing significant dilution. Former Treeline shareholders will control 84% of the combined company.
Added in current filing · verify on EDGAR →
Standard BioTools and Treeline expect the Board of Directors of the combined company will consist of 12 members, with ten members designated by Treeline and two members designated by Standard BioTools. The parties also expect that, immediately after the Effective Time, Dr. Josh Bilenker, currently the chief executive officer and co-founder of Treeline, will be appointed as Chief Executive Officer of the combined company, Dr. Jeff Engelman, currently the chief scientific officer and co-founder of Treeline, will be appointed as Chief Scientific Officer of the combined company, and Spencer Smith, currently the chief financial officer of Treeline, will be appointed as Chief Financial Officer of the combined company.
Treeline executives will assume all key leadership roles in the combined company. The board will have 12 members, with Treeline designating 10 and Standard BioTools only 2. Treeline's CEO, CSO, and CFO will become the combined company's CEO, CSO, and CFO respectively, reflecting Treeline's dominant position in the merger.
Added in current filing · verify on EDGAR →
Under the Merger Agreement, Standard BioTools must use its commercially reasonable efforts to effect the sale, license, transfer, disposition, divestiture or other monetization of its mass cytometry and microfluidics businesses (the “Legacy Business” and each such transaction, a “Legacy Transaction”). If Standard BioTools has not entered into a definitive agreement for the disposition of any portion of the Legacy Business on or before the date the Registration Statement is declared effective under the Securities Act of 1933, as amended (the “Securities Act”), Standard BioTools is required to commence mutually agreed wind-down activities with respect to that portion of the Legacy Business.
Standard BioTools is required to sell or otherwise dispose of its existing mass cytometry and microfluidics businesses. If these businesses cannot be sold by the time the merger registration statement becomes effective, the company must begin winding them down. This represents a complete exit from Standard BioTools' current core operations.
Added in current filing · verify on EDGAR →
Prior to the Effective Time, Standard BioTools expects to declare a dividend to Standard BioTools stockholders as of the close of business on the last business day prior to the day on which the Effective Time occurs in the form of one contingent value right (each, a “CVR”) for each outstanding share of Standard BioTools Common Stock held by such stockholder on such date. ... Pursuant to the CVR Agreement, the holder of each CVR will be entitled to receive a payment for each 12-month CVR payment period during the five year term of the CVR Agreement, consisting of a number of shares of Standard BioTools Common Stock (with fractional shares settled in cash) equal to such holder’s pro rata portion of the aggregate net proceeds received by the combined company during such 12-month CVR payment period from the following sources: (i) proceeds from any sale, disposition, or other monetization of the Legacy Business; (ii) proceeds from convertible notes or other investments held by Standard BioTools as of the Closing Date; (iii) earnout, milestone, royalty or other similar contingent payments due to Standard BioTools under contracts in effect as of the Closing Date, including payments from Illumina, Inc. pursuant to the Stock Purchase Agreement dated June 22, 2025; and (iv) any surplus in Standard BioTools’ net cash delivered at Closing as finally determined under the Merger Agreement. The maximum number of shares of common stock of the combined company which may be issued by the combined company pursuant to the CVR Agreement is 76,000,000.
Existing Standard BioTools shareholders will receive one CVR per share, entitling them to potential future payments over five years from proceeds of legacy business sales, existing investments, earnouts (including from Illumina), and excess cash. Payments will be made in shares of the combined company, capped at 76 million shares total. However, there is no guarantee any payments will be made, and the CVRs are non-transferable contractual rights with no voting or dividend rights.
Event · Item 3.02 — Unregistered Sales of Equity Securities
Standard BioTools issued unregistered shares in a merger via private placement under Securities Act exemptions.
Added in current filing · verify on EDGAR →
Certain of the shares of Standard BioTools Common Stock being issued in the Merger will be issued in private placements exempt from registration under Section 4(a) (2) of the Securities Act and/or Regulation D promulgated thereunder, because the offer and sale of such securities does not involve a “public offering” as defined in Section 4(a) (2) of the Securities Act.
Standard BioTools disclosed that it is issuing shares of its common stock as part of a merger transaction. These shares are being issued through private placements that are exempt from SEC registration requirements under Section 4(a)(2) and Regulation D, meaning they are not being offered to the general public. This is a standard structure for merger consideration involving unregistered securities.
Event · Item 5.01 — Changes in Control of Registrant
Standard Biotools disclosed a change in control of the registrant, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
Item 5.01 Changes in Control of Registrant. To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
The company disclosed a change in control of the registrant under Item 5.01. The specific details of this control change are referenced in Item 1.01 of the same 8-K filing, which was not provided in the excerpt. A change in control typically involves a transaction where a new party acquires majority ownership or voting power.
Event · Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Compensation
Standard Biotools disclosed officer or director changes, with details incorporated by reference from Item 1.01.
Added in current filing · verify on EDGAR →
To the extent required by this Item, the information included in Item 1.01 of this Current Report on Form 8-K is incorporated herein by reference.
The company disclosed changes related to directors or certain officers under Item 5.02, but the substantive details are referenced in Item 1.01 of the same 8-K filing, which was not provided in this excerpt. Item 5.02 typically covers departures, appointments, or compensatory arrangements for executive officers and directors.
Event · Item 7.01 — Regulation FD Disclosure
Standard BioTools announced execution of merger agreement with Treeline, disclosed via press release and investor presentations.
Added in current filing · verify on EDGAR →
On June 8, 2026, Standard BioTools and Treeline issued a joint press release announcing the execution of the Merger Agreement (the “Press Release”), and Standard BioTools included prepared remarks and an investor presentation on its website.
Standard BioTools executed a merger agreement with Treeline on June 6, 2026, and publicly announced it on June 8, 2026. The company disclosed this through multiple channels including a joint press release, prepared remarks, investor presentation, and employee town hall. This represents a significant corporate transaction that will require stockholder approval and regulatory clearance.
Added in current filing · verify on EDGAR →
the potential for Standard BioTools stockholders to receive consideration pursuant to the CVRs; expectations regarding the trading of the combined company’s common stock on Nasdaq after the closing of the Transactions
The merger structure includes contingent value rights (CVRs) that may provide additional consideration to Standard BioTools stockholders. The combined company's stock is expected to trade on Nasdaq following transaction close. This indicates stockholders may receive both immediate merger consideration and potential future payments through CVRs.
Added in current filing · verify on EDGAR →
the risk that the potential dispositions of Standard BioTools’ Mass Cytometry and Microfluidics businesses may not be completed on favorable terms or at all
Standard BioTools disclosed potential plans to divest its Mass Cytometry and Microfluidics business units. These dispositions are described as risks that may not complete on favorable terms or at all, suggesting they are contemplated but not finalized. This would represent a significant restructuring of the company's business portfolio alongside the merger.
Added in current filing · verify on EDGAR →
In connection with the proposed transaction and required stockholder approval, Standard BioTools intends to file with the SEC a registration statement on Form S-4 that will include a proxy statement and a prospectus of Standard BioTools.
The merger requires Standard BioTools stockholder approval, and the company will file an S-4 registration statement containing a proxy statement and prospectus. Stockholders will vote on whether to approve the transaction, making this a critical milestone for deal completion.
Added in current filing · verify on EDGAR →
the risk that Standard BioTools could fail to maintain the listing of the Standard BioTools Common Stock on Nasdaq
The company disclosed a risk that it may fail to maintain its Nasdaq listing. This suggests potential compliance issues or concerns about meeting continued listing standards, which could affect stock liquidity and investor access if the stock were delisted.
Event · Item 9.01 — Financial Statements and Exhibits
Standard BioTools announced a merger agreement with Treeline Biosciences, including voting agreements, lock-ups, and CVRs.
Added in current filing · verify on EDGAR →
Agreement and Plan of Merger and Reorganization, by and among Treeline Biosciences, Inc., Standard BioTools Inc. and Siri Merger Sub, Inc. dated as of June 6, 2026.
Standard BioTools entered into a definitive merger agreement with Treeline Biosciences on June 6, 2026, using Siri Merger Sub as the acquisition vehicle. The filing includes voting agreements, lock-up agreements, and a contingent value rights (CVR) agreement, indicating structured deal terms with shareholder protections and potential earnout provisions.
Added in current filing · verify on EDGAR →
Press Release, dated as of June 8, 2026.
The company issued a press release on June 8, 2026, and provided prepared remarks, investor presentation, and town hall presentation materials to communicate the merger transaction to stakeholders. These materials likely contain deal rationale, financial terms, and strategic benefits.
Added in current filing · verify on EDGAR →
Portions of this exhibit have been omitted pursuant to Item 601(a) (5) of Regulation S-K. Standard BioTools agrees to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission upon request; provided that Standard BioTools may request confidential treatment pursuant to Rule 24b-2 under the Exchange Act for any exhibits or schedules so furnished.
Certain schedules and exhibits to the merger agreement have been redacted from public disclosure under SEC rules, with the company reserving the right to request confidential treatment. This is standard practice for merger agreements containing commercially sensitive information such as pricing details, breakup fees, or competitive terms.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify